Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allogenic Hematopoietic Stem Cell Transplantation for Autoimmune Disease

Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens

Bone Marrow Transplantation volume 32, pages S81–S83 (2003)Cite this article

Summary:

Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that further study of autologous HSCT especially under phase III design is warranted. However, the ultimate goal of HSCT is cure of otherwise incurable autoimmune diseases. For this reason, allogeneic HSCT in carefully selected high-risk patients with autoimmune diseases using strategies to minimize both regimen-related toxicity and graft-versus-host disease (GVHD) is ongoing at Northwestern University and will be reviewed briefly.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hinterberger W, Hinterberger-Fischer M, Marmont AM . Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favourably affects outcomes after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant 2002; 11: 753–759.

    Article  Google Scholar 

  2. Slavin S, Nagler A, Varadi G, Or R . Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukaemia and severe psoriasis and psoriatic polyarthritis. Exp Hematol 2000; 28: 853–857.

    Article  CAS  Google Scholar 

  3. Li H, Kaufman CL, Boggs SS et al. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J Immunol 1996; 156: 380–388.

    CAS  Google Scholar 

  4. Wang B, Yamamoto Y, El-Badri NS, Good NA . Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice. Proc Nat Acad Sci USA 1999; 96: 3012–3016.

    Article  CAS  Google Scholar 

  5. Wang BY, Cherry, El-Badri NS, Good RA . Prevention of development of autoimmune disease in BXSB mice by mixed bone marrow transplantation. Proc Nat Acad Sci USA 1997; 94: 12065–12069.

    Article  CAS  Google Scholar 

  6. Delaney CP, Murase N, Chen-Woan M et al. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. J Clin Invest 1996; 97: 217–225.

    Article  CAS  Google Scholar 

  7. Gaur LK, Kennedy E, Nitta Y et al. Induction of donor-specific tolerance to islet allografts in nonhuman primates. Ann NY Acad Sci 2002; 958: 194–198.

    Article  Google Scholar 

  8. Wu T, Levay-Young B, Heuss N et al. Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy. Transplantation 2002; 74: 22–27.

    Article  CAS  Google Scholar 

  9. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthrits Rheum 1994; 37: 481–494.

    Article  CAS  Google Scholar 

  10. Erhardt CC, Mumford PA, Venables PJ, Maini RN . Factors predicting a poor life prognosis in rheumatoid arthritis: an eight-year prospective study. Ann Rheum Dis 1989; 48: 7–13.

    Article  CAS  Google Scholar 

  11. Prior P, Symmons DPM, Scott DL et al. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984; 23: 92–99.

    Article  CAS  Google Scholar 

  12. Medsger TA, Masi AT, Rodnan GP et al. Survival with systemic sclerosis (scleroderma). Ann Intern Med 1971; 75: 369–376.

    Article  Google Scholar 

  13. Wynn J, Fineberg N, Matzer L et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985; 110: 123–127.

    Article  CAS  Google Scholar 

  14. Altman RD, Medsger Jr TA, Bloch DA, Michel BA . Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403–413.

    Article  CAS  Google Scholar 

  15. Bryan C, Knight C, Black CM, Silman AJ . Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660–2667.

    Article  CAS  Google Scholar 

  16. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy 2001; 3: 197–201.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Immunotherapy, Northwestern University Medical School, Chicago, IL, USA

    Y Oyama, A E Traynor, W Barr & R K Burt

Authors
  1. Y Oyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A E Traynor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Barr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R K Burt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oyama, Y., Traynor, A., Barr, W. et al. Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens. Bone Marrow Transplant 32 (Suppl 1), S81–S83 (2003). https://doi.org/10.1038/sj.bmt.1703950

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703950

Keywords

This article is cited by

Search

Advanced search

Quick links